CSOP China Healthcare Disruption Index ETF (HKG:3174)
Hong Kong · Delayed Price · Currency is HKD 4.280
+0.176 (4.29%)
At close: Sep 5, 2025
4.29% (1Y)
| Assets | 1.18B |
| Expense Ratio | 1.50% |
| PE Ratio | 31.43 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +150.00% |
| Volume | 1,132,500 |
| Open | 4.136 |
| Previous Close | 4.104 |
| Day's Range | 4.116 - 4.310 |
| 52-Week Low | 1.670 |
| 52-Week High | 4.328 |
| Beta | 0.44 |
| Holdings | 24 |
| Inception Date | Jul 21, 2021 |
About 3174
CSOP China Healthcare Disruption Index ETF is an exchange-traded fund directly investing in companies. It prefers to invest in companies based out of Hong Kong. It primarily invests the healthcare- pharmaceutical and medical device companies.
Asset Class Equity
Category Total Market
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3174
Provider CSOP
Index Tracked WISE Samsung Group Value Index- KRW - Benchmark Price Return
Performance
3174 had a total return of 150.00% in the past year, including dividends. Since the fund's inception, the average annual return has been -12.77%.
Top 10 Holdings
75.84% of assets| Name | Symbol | Weight |
|---|---|---|
| Sino Biopharmaceutical Limited | 1177 | 9.42% |
| WuXi Biologics (Cayman) Inc. | 2269 | 8.91% |
| Innovent Biologics, Inc. | 1801 | 8.69% |
| WuXi AppTec Co., Ltd. | 2359 | 8.54% |
| CSPC Pharmaceutical Group Limited | 1093 | 8.36% |
| Akeso, Inc. | 9926 | 7.66% |
| Hansoh Pharmaceutical Group Company Limited | 3692 | 7.33% |
| Jiangsu Hengrui Medicine Co., Ltd. | 1276 | 6.05% |
| Alibaba Health Information Technology Limited | 0241 | 5.76% |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 2196 | 5.12% |